PharmaVoice

MARCH 29, 2023

Psilera founder’s “third eye” approach to psychedelics ushers them into the therapeutic realm

105

105

Fierce Healthcare

MARCH 29, 2023

Signify Health CEO says CVS deal will 'turbocharge' home health provider's roadmap hlandi Wed, 03/29/2023 - 19:57

110

110

Fierce Pharma

MARCH 27, 2023

BioNTech surprises analysts with low revenue guidance as COVID-19 vaccine demand wavers fkansteiner Mon, 03/27/2023 - 09:35

Vaccines 111

Vaccines 111

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. In its FY 2022 report, BioNTech has identified herpes simplex virus (HSV), malaria, and shingles as disease targets.

Vaccines 106

Vaccines 106

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.

Dosage

PharmaVoice

MARCH 28, 2023

The Supreme Court will now decide whether Amgen can protect Repatha as a whole class of drugs or whether Sanofi’s rival product Praluent can retain a place in the market

98

98

Fierce Healthcare

MARCH 29, 2023

UnitedHealthcare to begin reducing prior authorizations this summer pminemyer Wed, 03/29/2023 - 17:02

110

110

Pharmaceutical Technology

MARCH 29, 2023

Viking Therapeutics has announced the start of a Phase I clinical study to evaluate its dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735.

Dosage 98

Dosage Labelling FDA 98

Fierce Pharma

MARCH 27, 2023

Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries esagonowsky Mon, 03/27/2023 - 09:19

102

102

Fierce Healthcare

MARCH 28, 2023

ViVE 2023: Amazon Pharmacy integrates coupons in latest bid to target affordability of branded drugs hlandi Tue, 03/28/2023 - 15:24

107

107

Pharmafile

MARCH 27, 2023

The FDA has released a draft of new guidance for accelerated approval for oncology therapeutics, highlighting the need for stricter clinical trial design. read more Medical Communications

FDA 72

FDA Communication 72

Pharmaceutical Technology

MARCH 29, 2023

Regeneron Pharmaceuticals has collaborated with Sonoma Biotherapeutics to discover, develop and commercialise new regulatory T cell (Treg) therapies for autoimmune diseases.

98

98

Fierce Pharma

MARCH 27, 2023

Duo no more: After M&A spree, Pfizer parts ways with Merck KGaA on Bavencio zbecker Mon, 03/27/2023 - 17:42

96

96

Fierce Healthcare

MARCH 27, 2023

ViVE 2023: UnitedHealth's new tech exec on how the payer giant is aiming to accelerate transformation pminemyer Mon, 03/27/2023 - 22:48

110

110

Pharmafile

MARCH 29, 2023

Netris Pharma has announced that it has dosed its first patient in the Lap-NET1 study for the safety and efficacy of anti-netrin-1 antibody NP137 in combination with mFOLFIRINOX as a first-line treatment for patients with locally advanced pancreatic ductal adenocarcinoma.

64

64

Pharmaceutical Technology

MARCH 27, 2023

Regenerative medicines in early-stage development (preclinical, discovery, or investigational new drug [IND]/ clinical trial application [CTA] filed status) have seen a change in drug targets compared to therapies in late-stage development (Phase II to pre-registration stage).

97

97

Fierce Pharma

MARCH 27, 2023

Look out, Lilly. Novartis touts 'consistent benefit' for Kisqali in broad early-stage breast cancer aliu Mon, 03/27/2023 - 10:51

96

96

Fierce Healthcare

MARCH 28, 2023

Hospitals feel congressional heat over compliance with price transparency rule rking Tue, 03/28/2023 - 17:11

Hospitals 105

Hospitals 105

European Pharmaceutical Review

MARCH 29, 2023

Pembrolizumab (Keytruda) has been recommended in National Institute for Health and Care Excellence (NICE) final draft guidance for advanced cervical cancer.

Chemotherapy 85

Chemotherapy 85

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D).

Communication 94

Communication 94

Fierce Pharma

MARCH 28, 2023

Another rare disease M&A deal? BridgeBio draws buyout interest from Big Pharma: Bloomberg aliu Tue, 03/28/2023 - 10:22

90

90

Fierce Healthcare

MARCH 27, 2023

Value-based care enabler Wellvana clinches $84M to expand in existing, new markets agliadkovskaya Mon, 03/27/2023 - 14:48

107

107

Pharmafile

MARCH 29, 2023

Genialis, a computational precision medicine company, has announced that it’s raised more than $13m in Series A funding, co-led by Taiwania Capital and Debiopharm Innovation Fund.

Communication 59

Communication 59

Pharmaceutical Technology

MARCH 29, 2023

On March 28, the UK government announced that four UK life sciences companies will receive £277 million to help fund and advance manufacturing projects in medical diagnostics and human medicines.

Communication 90

Communication Vaccines 90

Fierce Pharma

MARCH 27, 2023

With FDA nod for a Novartis castoff, Pharming is set to market a second rare disease drug kdunleavy Mon, 03/27/2023 - 10:40

FDA 91

FDA 91

Fierce Healthcare

MARCH 29, 2023

Bipartisan Senate bill aims to take on Medicare Advantage up-coding practices rking Wed, 03/29/2023 - 17:02

99

99

Pharmafile

MARCH 29, 2023

AbbVie has shared that upadacitinib (Rinvoq) has been shown to be effective in treating patients with moderately-to-severely-active systemic lupus erythematosus (SLE).

59

59

PharmaVoice

MARCH 28, 2023

Ahead of turbulent market conditions, EY analyst Arda Ural encourages companies to rethink their sales strategy

59

59

Fierce Pharma

MARCH 27, 2023

In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda aliu Mon, 03/27/2023 - 15:40

90

90

Fierce Healthcare

MARCH 28, 2023

ViVe 2023: CancerX co-hosts Moffitt Cancer Center, Digital Medicine Society, unveil 'Moonshot' digital health effort hlandi Tue, 03/28/2023 - 07:36

98

98

Pharmafile

MARCH 28, 2023

Novo Nordisk has announced headline results from the phase 3b PIONEER PLUS trial for the safety and efficacy of once-daily oral semaglutide 25mg and 50mg versus 14mg as an add-on to a stable dose of 1-3 oral antidiabetic medicines in patients with type 2 diabetes.

59

59

Pharmaceutical Commerce

MARCH 30, 2023

Deciphering the different "technology-first” and “technology-enabled” patient support programs.

52

52

Fierce Pharma

MARCH 28, 2023

FDA committee will hear Perrigo's OTC bid for birth control med Opill in May kdunleavy Tue, 03/28/2023 - 14:47

FDA 82

FDA 82

Fierce Healthcare

MARCH 28, 2023

Podnosis': Insight on the Ohio train derailment class-action lawsuit, and how data analytics can improve social risk factor identification tcarey Tue, 03/28/2023 - 14:07

84

84

Pharmafile

MARCH 27, 2023

Abberior has announced that it has placed a super-resolution STED microscope at MBC BioLabs, which is the leading San Francisco Bay Area biotech incubator network.

Communication 59

Communication 59

Pharmaceutical Commerce

MARCH 30, 2023

With the rapid rise of the specialty drug market, manufacturers are increasingly relying on new advances used by patient hubs to boost their levels of patient engagement.

52

52

Fierce Pharma

MARCH 29, 2023

Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications kdunleavy Wed, 03/29/2023 - 10:40

78

78